Cost-effectiveness of the recombinant zoster vaccine in the German population aged ≥60 years old

References

• Wiese-Posselt M, Siedler A, Mankertz A, Sauerbrei A, Hengel H, Wichmann O, Poethko-Muller C. Varicella-zoster virus seroprevalence in children and adolescents in the pre-varicella vaccine era, Germany. BMC Infect Dis. 2017;17(1):356. doi:10.1186/s12879-017-2461-2.
   PubMedGoogle Scholar
• Wutzler P, Farber I, Wagenpfeil S, Bisanz H, Tischer A. Seroprevalence of varicella-zoster virus in the German population. Vaccine. 2001;20(1–2):121–124. doi:10.1016/S0264-410X(01)00276-6.
   PubMed Web of Science ®Google Scholar
• Cohen JI. Herpes zoster. N Engl J Med. 2013;369(18):1766–1767. doi:10.1056/NEJMc1310369.
   PubMedGoogle Scholar
• Pinchinat S, Cebrian-Cuenca AM, Bricout H, Johnson RW. Similar herpes zoster incidence across Europe: results from a systematic literature review. BMC Infect Dis. 2013;13:.170. doi:10.1186/1471-2334-13-170.
   PubMed Web of Science ®Google Scholar
• Hillebrand K, Bricout H, Schulze-Rath R, Schink T, Garbe E. Incidence of herpes zoster and its complications in Germany, 2005-2009. J Infect. 2015;70(2):178–186. doi:10.1016/j.jinf.2014.08.018.
   PubMed Web of Science ®Google Scholar
• Opstelten W, Mauritz JW, De Wit NJ, van Wijck AJ, Stalman WA, van Essen GA. Herpes zoster and postherpetic neuralgia: incidence and risk indicators using a general practice research database. Fam Pract. 2002;19(5):471–475. doi:10.1093/fampra/19.5.471.
   PubMed Web of Science ®Google Scholar
• Drolet M, Brisson M, Schmader KE, Levin MJ, Johnson R, Oxman MN, Patrick D, Blanchette C, Mansi JA. The impact of herpes zoster and postherpetic neuralgia on health-related quality of life: a prospective study. Can Med Assoc J. 2010;182(16):1731–1736. doi:10.1503/cmaj.091711.
   PubMed Web of Science ®Google Scholar
• Oster G, Harding G, Dukes E, Edelsberg J, Cleary PD. Pain, medication use, and health-related quality of life in older persons with postherpetic neuralgia: results from a population-based survey. J Pain. 2005;6(6):356–363. doi:10.1016/j.jpain.2005.01.359.
   PubMed Web of Science ®Google Scholar
• Ultsch B, Koster I, Reinhold T, Siedler A, Krause G, Icks A, Schubert I, Wichmann O. Epidemiology and cost of herpes zoster and postherpetic neuralgia in Germany. Eur J Health Econ. 2013;14(6):1015–1026. doi:10.1007/s10198-012-0452-1.
   PubMed Web of Science ®Google Scholar
• Ultsch B, Siedler A, Rieck T, Reinhold T, Krause G, Wichmann O. Herpes zoster in Germany: quantifying the burden of disease. BMC Infect Dis. 2011;11:.173. doi:10.1186/1471-2334-11-173.
   PubMed Web of Science ®Google Scholar
• Varghese L, Standaert B, Olivieri A, Curran D. The temporal impact of aging on the burden of herpes zoster. BMC Geriatr. 2017;17(1):30. doi:10.1186/s12877-017-0420-9.
   PubMedGoogle Scholar
• STIKO. Standard operating procedure of the German standing committee on vaccinations (STIKO) for the systematic development of vaccination recommendations, Version 3.0. Berlin; 2016 Mar 16th [ accessed 2018 Jan 15]. https://www.rki.de/EN/Content/infections/Vaccination/methodology/SOP.pdf?__blob=publicationFile.
   Google Scholar
• Robert Koch Institut. Standing Committee on Vaccination (STIKO). 2016 Aug 29 [ accessed 2017 Oct 3]. http://www.rki.de/EN/Content/infections/Vaccination/Vaccination_node.html.
   Google Scholar
• Siedler A, Koch J, Ultsch B, Garbe E, von Kries R, Ledig T, Mertens T, Überla K, Zepp F, Hengel H. Background paper to the decision not to recommend a standard vaccination with the live attenuated herpes zoster vaccine for the elderly in Germany. Bundesgesundheitsblatt. 2017;60(10):1162–1179. doi:10.1007/s00103-017-2618-6.
   Google Scholar
• European Medicines Agency. Zostavax - EPAR - product information - summary of product chracteristics. 2018 Jan 18 [ accessed 2018 Apr 05]. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000674/WC500053462.pdf.
   Google Scholar
• European Commission - Public Health. Community register of medicinal products for human use - Product information - Shingrix. 2018 Apr 03 [ accessed 2018 Apr 05]. http://ec.europa.eu/health/documents/community-register/html/h1272.htm.
   Google Scholar
• Cunningham AL, Lal H, Kovac M, Chlibek R, Hwang SJ, Diez-Domingo J, Godeaux O, Levin MJ, McElhaney JE, Puig-Barbera J, et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N Engl J Med. 2016; 375(11):1019–1032. doi:10.1056/NEJMoa1603800.
   PubMed Web of Science ®Google Scholar
• Lal H, Cunningham AL, Godeaux O, Chlibek R, Diez-Domingo J, Hwang S-J, Levin MJ, McElhaney JE, Poder A, Puig-Barberà J, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015;372(22):2087–2096. doi:10.1056/NEJMoa1501184.
   PubMed Web of Science ®Google Scholar
• Curran D, Van Oorschot D, Varghese L, Oostvogels L, Mrkvan T, Colindres R, von Krempelhuber A, Anastassopoulou A. Assessment of the potential public health impact of herpes zoster vaccination in Germany. Hum Vaccin Immunother. 2017;13(10):2213–2221. doi:10.1080/21645515.2017.1345399.
   PubMed Web of Science ®Google Scholar
• Ultsch B, Weidemann F, Koch J, Siedler A. Projektbericht: modellierung von epidemiologischen und gesundheitsökonomischen Effekten von Impfungen zur Prävention von Herpes zoster. 2017 Aug 01 [ accessed 2018 Apr 05]. https://www.rki.de/DE/Content/Infekt/Impfen/ImpfungenAZ/Zoster/Modellierung_Zoster_Impfung.pdf?__blob=publicationFile.
   Google Scholar
• Schmidt-Ott R, Schutter U, Simon J, Nautrup BP, von Krempelhuber A, Gopala K, Anastassopoulou A, Guignard A, Curran D, Matthews S, et al. Incidence and costs of herpes zoster and postherpetic neuralgia in German adults aged ≥50 years: A prospective study. J Infect. 2018;76:475–482. doi:10.1016/j.jinf.2018.02.001.
   PubMed Web of Science ®Google Scholar
• Horn J, Damm O, Kretzschmar M, Karch A, Siedler A, Ultsch B, Weidemann F, Greiner W, Mikolaczyk R Modellierung der effekte des varizellen-impfprogramms in Deutschland. Abschlussbericht, Version 1.2. 2014 Sep 16 [ accessed 2017 Jun 15]. http://www.rki.de/DE/Content/Infekt/Impfen/Forschungsprojekte/abgeschlossene_Projekte/Varizellen-Impfung/Abschlussbericht.pdf?__blob=publicationFile.
   Google Scholar
• Bresse X, Annemans L, Preaud E, Bloch K, Duru G, Gauthier A. Vaccination against herpes zoster and postherpetic neuralgia in France: a cost-effectiveness analysis. Expert Rev Pharmacoecon Outcomes Res. 2013;13(3):393–406. doi:10.1586/erp.13.19.
   PubMed Web of Science ®Google Scholar
• van Hoek AJ, Gay N, Melegaro A, Opstelten W, Edmunds WJ. Estimating the cost-effectiveness of vaccination against herpes zoster in England and Wales. Vaccine. 2009;27(9):1454–1467. doi:10.1016/j.vaccine.2008.12.024.
   PubMed Web of Science ®Google Scholar
• Kawai K, Preaud E, Baron-Papillon F, Largeron N, Acosta CJ. Cost-effectiveness of vaccination against herpes zoster and postherpetic neuralgia: a critical review. Vaccine. 2014;32(15):1645–1653. doi:10.1016/j.vaccine.2014.01.058.
   PubMed Web of Science ®Google Scholar
• Prosser LA Economic evaluation of vaccination for prevention of herpes zoster and related complications. Presentation to the advisory committee on immunization practices. 2017 [ accessed 2018 May] https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2017-10/zoster-03-prosser.pdf
   Google Scholar
• Le P, Rothberg MB. Cost-effectiveness of the adjuvanted herpes zoster subunit vaccine in older adults. JAMA Intern Med. 2018;178(2):248–258. doi:10.1001/jamainternmed.2017.7431.
   PubMed Web of Science ®Google Scholar
• Anastassopoulou A, Curran D, Schmidt‐Ott R, Schutter U, Simon J, Poulsen Nautrup B, Matthews S Herpes Zoster and postherpetic neuralgia: quality of life and healthcare utilization, a German study; Paper presented at: ISPOR 19th Annual European Congress; 2016 Oct 31; Vienna (Austria). doi:10.1016/j.jval.2016.09.427
   Google Scholar
• Dooling KL, Guo A, Patel M, Lee GM, Moore K, Belongia EA, Harpaz R. Recommendations of the advisory committee on immunization practices for use of herpes zoster vaccines. MMWR Morb Mortal Wkly Rep. 2018;67(3):103–108. doi:10.15585/mmwr.mm6703a5.
   PubMed Web of Science ®Google Scholar
• STIKO. Modelling methods for predicting epidemiological and health economic effects of vaccinations – guidance for analyses to be presented to the German Standing Committee on Vaccination (STIKO). Berlin; last updated: 2016 Mar 16 [ accessed 2018 Apr 05]. http://www.rki.de/EN/Content/infections/Vaccination/methodology/Guidance_for_analyses.pdf?__blob=publicationFile.
   Google Scholar
• Neine M, Curran D. An algorithm to develop correlated multivariate non-normal (E.G. Beta, Gamma, Log-Normal) distributions to be used in probabilistic sensitivity analyses (PSAs). Value in Health. 2017;20(9):A757. doi:10.1016/j.jval.2017.08.2134.
   Web of Science ®Google Scholar
• Brettschneider C, Luck T, Fleischer S, Roling G, Beutner K, Luppa M, Behrens J, Riedel-Heller SG, Konig HH. Cost-utility analysis of a preventive home visit program for older adults in Germany. BMC Health Serv Res. 2015;15:.141. doi:10.1186/s12913-015-0817-0.
   PubMed Web of Science ®Google Scholar
• Dolk C, Eichner M, Welte R, Anastassopoulou A, Van Bellinghen LA, Poulsen Nautrup B, Van Vlaenderen I, Schmidt-Ott R, Schwehm M, Postma M. Cost-utility of quadrivalent versus trivalent influenza vaccine in Germany, Using an individual-based dynamic transmission model. Pharmacoeconomics. 2016;34(12):1299–1308. doi:10.1007/s40273-016-0443-7.
   PubMed Web of Science ®Google Scholar
• Krejczy M, Harenberg J, Marx S, Obermann K, Frolich L, Wehling M. Comparison of cost-effectiveness of anticoagulation with dabigatran, rivaroxaban and apixaban in patients with non-valvular atrial fibrillation across countries. J Thromb Thrombolysis. 2014;37(4):507–523. doi:10.1007/s11239-013-0989-6.
   PubMed Web of Science ®Google Scholar
• DeStatis - Statistisches Bundesamt. Bevölkerung Deutschlands bis 2060 - Ergebnisse der 13. koordinierten Bevölkerungsvorausberechnung. 2015 Apr 28. Wiesbaden [ accessed 2017 Jun 15]. https://www.destatis.de/DE/Publikationen/Thematisch/Bevoelkerung/VorausberechnungBevoelkerung/BevoelkerungDeutschland2060_5124202159004.pdf?__blob=publicationFile.
   Google Scholar
• Paul E, Thiel T. Zur epidemiologie der varizella-zoster-infektion. Ergebnisse einer prospektiven Erhebung im Landkreis Ansbach. [Epidemiology of varicella zoster infection. Results of a prospective study in the Ansbach area]. Hautarzt. 1996;47(8):604–609. doi:10.1007/s001050050476.
   PubMedGoogle Scholar
• Schiffner-Rohe J, Köster I, Beillat M, Lilie HM, Schubert I. Ressourcenverbrauch und kosten von herpes zoster und postherpetischer neuralgie in Deutschland [Resource consumption and health care costs of Herpes zoster and postherpetic neuralgia in Germany]. Gesundh Ökon Qual Manag. 2011;16(4):216–223. doi:10.1055/s-0029-1245896.
   Google Scholar
• Ultsch B, Weidemann F, Reinhold T, Siedler A, Krause G, Wichmann O. Health economic evaluation of vaccination strategies for the prevention of herpes zoster and postherpetic neuralgia in Germany. BMC Health Serv Res. 2013;13:.359. doi:10.1186/1472-6963-13-359.
   PubMed Web of Science ®Google Scholar
• Yawn BP, Saddier P, Wollan PC, St Sauver JL, Kurland MJ, Sy LS. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc. 2007;82(11):1341–1349. doi:10.4065/82.11.1341.
   PubMed Web of Science ®Google Scholar
• Bricout H, Haugh M, Olatunde O, Prieto RG. Herpes zoster-associated mortality in Europe: a systematic review. BMC Public Health. 2015;15:.466. doi:10.1186/s12889-015-1753-y.
   PubMed Web of Science ®Google Scholar
• Le P, Rothberg MB. Cost-effectiveness of herpes zoster vaccine for persons aged 50 years. Ann Intern Med. 2015;163(7):489–497. doi:10.7326/M15-0093.
   PubMed Web of Science ®Google Scholar